GT BIOPHARMA ANNOUNCES FDA DATA – GTB-3550 TriKE™ REDUCES CANCER CELLS BY …,

Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, … Correlative studies showed no shedding of CD16 from patient’s NK cells, …, Erica Warlick, M.D, Principal Investigator for the GTB-3550 clinical trial, … Correlative studies showed no shedding of CD16 from patient’s NK cells, …, Read More

Scroll to Top